Watch for sudden severe back or side pain, painful urination, blood in urine, nausea, or frequent urination
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
YoussefMMUnderwoodMDHuangYYHsiungSCLiuYSimpsonNRet al
If youre searching for the best GLP-1 for weight loss, youre not alonethese medications have become some of the most talked-about tools for achieving long-term fat loss, reducing appetite, and improving metabolic health
Lillys orforglipron, if approved as expected this month, will not only end Novos brief run as the only oral GLP-1 game in town, but it also comes with what may well be a consumer-friendly competitive edge
These are our neighbors with intellectual disabilities, those in wheelchairs with neurological and orthopedic conditions or with brain or spinal cord injuries